Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Trifluridine and Tipiracil Tablets is a nucleoside anti-metabolic and anti-cancer compound
developed by Taiho (Dapeng) Co., Ltd., Japan, for the treatment of advanced colorectal cancer
that inoperable resection, and progressed or relapsed after standard treatment. This study
mainly evaluates bioequivalence, safety and tolerance of Trifluridine and Tipiracil Tablets
in colorectal cancer patients.